CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on November 5, 2019
![[htbx_corresp002.gif]](htbx_corresp002.gif)
Heat Biologics, Inc.
677 Davis Drive
Morrisville, North Carolina 27560
November 5, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Paul Fischer
|
Re: Heat Biologics, Inc. |
|
|
Registration Statement on Form S-1 |
|
|
File No. 333-234105 |
|
Dear Mr. Fischer:
Heat Biologics, Inc. (the Company) hereby respectfully requests withdrawal of its acceleration request letter filed as correspondence via EDGAR on November 1, 2019, which requested that the above-referenced Registration Statement on Form S-1 (File No. 333-234105) become effective on Tuesday, November 5, 2019 at 5:00 p.m., New York City Time, or as soon as reasonably practicable thereafter. The Registrant is no longer requesting that such Registration Statement be declared effective at this time and the Registrant hereby formally withdraws its request for acceleration of the effective date.
If you have any questions regarding the foregoing, please contact our counsel, Patrick Egan at (914) 557-5574 or Leslie Marlow at (516) 496-2223 or (212) 907-6457.
|
|
|
|
|
Very truly yours, |
|
|
|
|
|
|
|
Heat Biologics, Inc. |
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Jeffrey Wolf |
|
|
|
Name: Jeffrey Wolf |
|
|
|
Title: Chief Executive Officer |
cc: Leslie Marlow, Gracin & Marlow, LLP
Patrick Egan, Gracin & Marlow, LLP